Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1108P - Folfirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carsinomas

Date

16 Sep 2021

Session

ePoster Display

Presenters

Baddar Pervaiz Butt

Citation

Annals of Oncology (2021) 32 (suppl_5): S906-S920. 10.1016/annonc/annonc678

Authors

B.P. Butt1, H.L. Stokmo2, M. Ladekarl3, E. Mitkina Tabaksblat4, H. Sorbye5, M.E. Revheim6, G.O. Hjortland7

Author affiliations

  • 1 Department Of Oncology, Entes Neuroendocrine Tumor Center Of Excellence, Oslo University Hospital, 0450 - Oslo/NO
  • 2 Department Of Nuclear Medicine, Division Of Radiology And Nuclear Medicine, Oslo University Hospital, 0424 - Oslo/NO
  • 3 Department Of Oncology, Cinical Cancer Research Center, Aalborg University Hospital, 9000 - Aalborg/DK
  • 4 Department Of Oncology, Enets Neuroendocrine Tumor Center Of Excellence, Aarhus University Hospital, 8000 - Aarhus/DK
  • 5 Department Of Oncology, Department Of Clinical Science, Haukeland Universitetssykehus, 5021 - Bergen/NO
  • 6 Department Of Nuclear Medicine, Division Of Radiology And Nuclear Medicine, Instituteof Clinical Medicine, Enets Neuroendocrine Tumor Center Of Excellence, Oslo University Hospital, 0424 - Oslo/NO
  • 7 Department Of Oncology, Entes Neuroendocrine Tumor Center Of Excellence, Oslo University Hospital, 0424 - Oslo/NO
More

Abstract 1108P

Background

Neuroendocrine neoplasms most commonly arise from the gastroenteropancreatic (GEP) system. The WHO classification of digestive system tumors describes four main types: Neuroendocrine tumor (NET) grades 1-3 and neuroendocrine carcinoma (NEC). NECs have an aggressive biology and are often diagnosed in an advanced stage associated with poor prognosis. First-line palliative chemotherapy is commonly carboplatin or cisplatin in combination with etoposide, while in second-line capecitabine-temozolomide, FOLFIRI or FOLFOX regimens are used. Few prospective studies have been done and data on efficacy is scarce. We conducted a retrospective study of patients with GEP-NEC treated with FOLFIRINOX, evaluating response to treatment and survival.

Methods

Patients diagnosed with GEP-NEC at three different centers and treated with FOLFIRINOX were identified and included in the study. Baseline demographics were collected at start of FOLFIRINOX. The Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria were used to assess the treatment response at computed tomography (CT).

Results

Thirty-seven patients between 2014 and 2020 were identified and included in the study. Median age was 53 years and female/male ratio was 1:1. Most of the patients were in WHO performance status 0 or 1 (86%). The most common primary tumor sites were colon (30%), pancreas (27%), oesophagus (10%)and rectum (10%). The median Ki67 was 80% (range 22%, 100%). Out of 37 patients treated, 8 (22%) patients received FOLFIRINOX as first-line treatment, 21 (57%) patients as second line treatment and 8 patients as third-line treatment or later. Overall response rate (ORR) (all lines) was 46% (17/37); i.e. complete response 0% (0/37), partial response 46% (17/37), stable disease 22% (8/37) and progressive disease 22% (8/37). Median overall survival (mOS) was 17,8 months (CI: 11,4 – 23,3). Median progression free survival from first course of FOLFIRINOX was 5,4 months (CI: 3,5 – 6,9).

Conclusions

FOLFIRINOX is an active regimen in the treatment of GEP-NEC and may be considered in the treatment of advanced disease. Prospective randomized trials are needed to compare efficacy among different chemotherapy regimens.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Oslo University Hospital.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.